User contributions for Omid Afkhami-Ardakani
Jump to navigation
Jump to search
2 November 2024
- 20:1220:12, 2 November 2024 diff hist +4,265 N Recarbrio Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Imipenem, Cilastatin, and Relebactam |aOrAn=an |drugClass=Antibacterial Combination |indicationType=treatment |indication=Complicated Urinary Tract Infections (cUTI), Complicated Intra-Abdominal Infections (cIAI), and Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) in patients 18 years and older. |adverseReactions=Nausea, Diarrhea, Headache, Fever, an..." current
25 October 2024
- 21:3921:39, 25 October 2024 diff hist +21 m Selinexor No edit summary current Tag: Visual edit
- 21:3221:32, 25 October 2024 diff hist +3,815 N Selinexor Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Selinexor |aOrAn=a |drugClass=Selective Inhibitor of Nuclear Export (SINE) |indicationType=treatment |indication=Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B-Cell Lymphoma (DLBCL) |hasBlackBoxWarning=Yes |adverseReactions=Nausea, fatigue, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, weight loss |blackBoxWarningTitle=Serious Hematologic a..."
16 October 2024
- 16:4116:41, 16 October 2024 diff hist +6,144 N Vyleesi Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Vyleesi |aOrAn=a |drugClass=Melanocortin receptor agonist |indicationType=treatment |indication=hypoactive sexual desire disorder (HSDD) in premenopausal women |adverseReactions=nausea (40%), flushing (20%), injection site reactions (13%), headache (11%), and vomiting (4.8%) |fdaLIADAdult=Vyleesi is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in pre..." current
19 September 2024
- 15:0215:02, 19 September 2024 diff hist +12,965 N Polivy Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Polivy |aOrAn=a |drugClass=HUMAN PRESCRIPTION DRUG LABEL |indicationType=treatment |indication=POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated: 1. in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise speci..." current